ASX-LISTED medication adherence specialist MedAdvisor yesterday had its shares placed in a trading halt, pending the release of an announcement expected later today.
The company said it was requesting the suspension in order to facilitate an orderly market in its securities, in the lead up to the release of details "regarding the signing of a significant commercial agreement by the company's US subsidiary, MedAdvisor Welam USA Inc".
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Mar 19
